Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2011

View Archived Issues

Phase I/II trial of mesenchymal stem cells for Crohn's disease-associated fistulas advances

Dopaminergic gene variations influence response to antipsychotics

New Toll-like receptor 7 agonist PF-4171455 selected for investigation for hepatitis C

Preclinical and clinical phase I data presented on THR-18 for stroke

Blood biomarkers can differentiate stroke and stroke-mimicking conditions

AstraZeneca's AZ-876 inhibits atherosclerosis and shows no inflammatory effects in vivo

Abbott updates highlights for fourth quarter of 2010

Threshold Pharma and FDA agree on SPA for phase III TH-302 trial in soft tissue sarcoma

Sanofi-aventis withdraws Anzemet for chemotherapy-induced nausea and vomiting

Pantarhei Bioscience seeks to acquire women's health activities from Organon

FDA approves aripiprazole for bipolar I disorder as an adjunct to mood stabilizers

Inspire Pharma discontinues development of denufosol for cystic fibrosis

DPZ and Ascenion sign license agreement for recombinant VP1-containing VLP

Acadra shows promise in phase I/IIa trial in chronic lymphocytic leukemia

Phase II trial of PXL-01 for prevention of postsurgical adhesions is extended to Germany

Novartis claims new inhibitors of serine/threonine-protein kinase D1

Dosing complete in phase I trial of HuCNS-SC in pediatric Pelizaeus-Merzbacher disease

Santhera regains rights to fipamezole from Biovail

Cytochroma begins phase IIb trial of CTAP-101 for vitamin D insufficiency in chronic kidney disease

Astellas' Protopic approved in Canada for prevention of eczema flares

Chimerix receives BARDA contract to develop CMX-001 for smallpox

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...